Electra Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for ELA026, an antibody therapy to treat hemophagocytic lymphohistiocytosis (HLH).
The ATLAS-2M study is designed to demonstrate the non-inferior antiviral activity, at 48 weeks of treatment, of long-acting cabotegravir and long-acting rilpivirine administered every eight weeks compared with
“This partnership is further evidence of Biogen’s ongoing commitment to multiple sclerosis and builds upon our deep experience in neuroscience and particularly in MS,” stated Michel Vounatsos, Chief Executive Officer
The submission includes data from two completed trials of RUCONEST® for the prophylaxis of HAE attacks: a randomized, double-blind, placebo-controlled trial and an open-label study. The two studies
The trial, dubbed WISTERIA, will assess the effectiveness of the pharma company’s experimental compound AZD1775, in combination with chemotherapy prior to surgery or with chemotherapy and radiotherapy after surgery.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
